BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10992481)

  • 1. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
    Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.
    Wu HY; Russell MW
    Infect Immun; 1993 Jan; 61(1):314-22. PubMed ID: 8418053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
    Price GA; Russell MW; Cornelissen CN
    Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic and mucosal antibody responses to group B streptococci following immunization of the colonic-rectal mucosa.
    Hordnes K; Digranes A; Haugen IL; Helland DE; Ulstein M; Jonsson R; Haneberg B
    J Reprod Immunol; 1995 Mar; 28(3):247-62. PubMed ID: 7473434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.
    Larsson C; Holmgren J; Lindahl G; Bergquist C
    Infect Immun; 2004 Feb; 72(2):1184-7. PubMed ID: 14742572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
    Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.
    Kozlowski PA; Williams SB; Lynch RM; Flanigan TP; Patterson RR; Cu-Uvin S; Neutra MR
    J Immunol; 2002 Jul; 169(1):566-74. PubMed ID: 12077289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates.
    Johansson EL; Rask C; Fredriksson M; Eriksson K; Czerkinsky C; Holmgren J
    Infect Immun; 1998 Feb; 66(2):514-20. PubMed ID: 9453604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
    Yang HH; Madoff LC; Guttormsen HK; Liu YD; Paoletti LC
    Infect Immun; 2007 Jul; 75(7):3455-61. PubMed ID: 17470542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
    Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
    Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
    Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
    Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection.
    Hvalbye BK; Aaberge IS; Løvik M; Haneberg B
    Infect Immun; 1999 Sep; 67(9):4320-5. PubMed ID: 10456869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells.
    Deifallah Yousif M; Felek A; Saydam M; Wilson S; Murdan S; Mawas F
    Vaccine; 2022 Oct; 40(42):6055-6063. PubMed ID: 36096970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.